Posted by Michael Wonder on 19 Jan 2023
NICE recommends reimbursement for Translarna
19 January 2023 - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy.
PTC Therapeutics today announced that the NICE has issued a final evaluation document recommending Translarna (ataluren) for reimbursement and use across the NHS in England and Wales.
